Publications

2021


  1. Rajamäki, K, Taira, A, Katainen, R, Välimäki, N, Kuosmanen, A, Plaketti, RM et al.. Genetic and epigenetic characteristics of inflammatory bowel disease associated colorectal cancer. Gastroenterology. 2021; :. doi: 10.1053/j.gastro.2021.04.042. PubMed PMID:33930428 .
  2. Cangiano, M, Grudniewska, M, Salji, MJ, Nykter, M, Jenster, G, Urbanucci, A et al.. Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer. Cancers (Basel). 2021;13 (9):. doi: 10.3390/cancers13092094. PubMed PMID:33925994 .
  3. Annala, M, Fu, S, Bacon, JVW, Sipola, J, Iqbal, N, Ferrario, C et al.. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021; :. doi: 10.1016/j.annonc.2021.03.205. PubMed PMID:33836265 .
  4. Cerqueira, JXM, Saavalainen, P, Kurppa, K, Laurikka, P, Huhtala, H, Nykter, M et al.. Independent and cumulative coeliac disease-susceptibility loci are associated with distinct disease phenotypes. J Hum Genet. 2021; :. doi: 10.1038/s10038-020-00888-5. PubMed PMID:33446885 .
  5. Vandekerkhove, G, Lavoie, JM, Annala, M, Murtha, AJ, Sundahl, N, Walz, S et al.. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021;12 (1):184. doi: 10.1038/s41467-020-20493-6. PubMed PMID:33420073 PubMed Central PMC7794518.
  6. Warner, E, Herberts, C, Fu, S, Yip, S, Wong, A, Wang, G et al.. BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clin Cancer Res. 2021;27 (6):1650-1662. doi: 10.1158/1078-0432.CCR-20-3708. PubMed PMID:33414135 .

Search PubMed